Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px
Document › Details

Argen-X N.V. (Argenx). (12/11/14). "Press Release: Argen-X Announces Advancement of Therapeutic Antibody Alliance with Shire". Breda & Ghent.

Organisations Organisation Argen-X N.V. (Argenx) (Euronext + Nasdaq: ARGX)
  Group Argen-X (Argenx) (Group)
  Organisation 2 Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ)
  Today Shire Ltd. (LSE: SHP, NASDAQ: SHPGY)
  Group Shire (Group)
Products Product SIMPLE Antibody™ discovery platform
  Product 2 therapeutic antibody
Index term Index term Shire–Argen-X: SIMPLE antibody discovery platform, 201202– collab €na create antibodies for rare genetic disease targets of Shire
Persons Person Van Hauwermeiren, Tim (Argen-X 201101 CEO before Ablynx BusDev Manager before P&G)
  Person 2 Seymour, Albert (Shire 201401 Head of Discovery Biology + Translational Research)
     


Shire to take one or more collaborative product candidates into preclinical development


arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that its partner Shire has exercised its option to advance into preclinical development one or more product candidates created out of a 2012 therapeutic antibody alliance between the two companies. As a result of the exercise, arGEN-X will receive a milestone payment from Shire.

Under the terms of the 2012 alliance, Shire was given the option to license promising leads of human antibody candidates identified and characterized by arGEN-X using the SIMPLE Antibody™ Platform. These therapeutic leads were based on targets provided to arGEN-X by Shire that are known to contribute to the pathophysiology of severe, rare genetic diseases.

“We are very pleased with Shire’s decision to exercise its option to further develop product candidates that came out of our initial discovery deal. We believe this decision is a reflection of the strength of our technology platform and its ability to deliver viable therapeutic candidates that reach disease targets previously considered inaccessible,” said Tim Van Hauwermeiren, CEO of arGEN-X. “We look forward to our continued work with Shire through the ongoing development and potential commercialization of product candidates born out of our therapeutic antibody alliance but also through our more recently established long-term strategic alliance.”

“The success of our therapeutic antibody collaboration with arGEN-X has led us to exercise our first option to a commercial license,” said Albert Seymour, Head of Research and Non-Clinical Development at Shire.

In June 2014, arGEN-X and Shire entered into a long-term strategic alliance which expanded upon the initial collaboration to include the use of the entire suite of arGEN-X human antibody discovery technologies.


For further information,

please contact:

Tim Van Hauwermeiren
Chief Executive Officer
+32 9 243 40 70

Eric Castaldi
Chief Financial Officer
+32 479 96 96 56

info@arGEN-X.com


arGEN-X BVBA (R&D Center)
Technologiepark 30
9052 Zwijnaarde
Belgium


Mark Swallow
David Dible
Citigate Dewe Rogerson
+44 207 282 2949
arGEN-X@citigatedr.co.uk

Beth DelGiacco
Stern Investor Relations
+1 212 362 1200
beth@sternir.com


About arGEN-X

arGEN-X is a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases. arGEN-X has generated a clinical pipeline of differentiated antibody candidates using its SIMPLE Antibody™ discovery platform. SIMPLE Antibody™ has a particular strength in addressing novel, complex disease targets that are difficult to access using established antibody technology platforms. Fc engineering technologies – NHance®, ABDEG™ and POTELLIGENT® – further enhance the therapeutic properties of SIMPLE Antibody™ leads in terms of their residence time in the body, their ability to clear disease targets or pathogenic antibodies and their cell killing potency through Antibody-Dependent Cell-mediated Cytotoxicity (ADCC), respectively. arGEN-X has leveraged its suite of antibody technologies in forging strategic collaborations with pharmaceutical and biotechnology companies to provide new approaches to diseases with unmet medical needs.


Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements arGEN-X makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. arGEN-X’ actual results may differ materially from those predicted by the forward-looking statements. arGEN-X undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

   
Record changed: 2017-04-17

Advertisement

Picture [iito] – Putting Information into Context 600x102px

More documents for Argen-X (Argenx) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px




» top